The Alpha-cell As Target for Type 2 Diabetes Therapy

Overview

Journal Rev Diabet Stud

Specialty Endocrinology

Date 2012 Jan 21

PMID 22262074

Citations 22

Authors

Mikkel Christensen

Jonatan I Bagger

Tina Vilsboll

Filip K Knop

Affiliations

Soon will be listed here.

Abstract

Glucagon is the main secretory product of the pancreatic alpha-cells. The main function of this peptide hormone is to provide sustained glucose supply to the brain and other vital organs during fasting conditions. This is exerted by stimulation of hepatic glucose production via specific G protein-coupled receptors in the hepatocytes. Type 2 diabetic patients are characterized by elevated glucagon levels contributing decisively to hyperglycemia in these patients. Accumulating evidence demonstrates that targeting the pancreatic alpha-cell and its main secretory product glucagon is a possible treatment for type 2 diabetes. Several lines of preclinical evidence have paved the way for the development of drugs, which suppress glucagon secretion or antagonize the glucagon receptor. In this review, the physiological actions of glucagon and the role of glucagon in type 2 diabetic pathophysiology are outlined. Furthermore, potential advantages and limitations of antagonizing the glucagon receptor or suppressing glucagon secretion in the treatment of type 2 diabetes are discussed with a focus on already marketed drugs and drugs in clinical development. It is concluded that the development of novel glucagon receptor antagonists are confronted with several safety issues. At present, available pharmacological agents based on the glucose-dependent glucagonostatic effects of GLP-1 represent the most favorable way to apply constraints to the alpha-cell in type 2 diabetes.

Citing Articles

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus.

He X, Zhao W, Li P, Zhang Y, Li G, Su H Front Pharmacol. 2025; 15:1483792.

PMID: 39902077 PMC: 11788294. DOI: 10.3389/fphar.2024.1483792.

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.

Nicze M, Dec A, Borowka M, Krzyzak D, Boldys A, Buldak L Int J Mol Sci. 2024; 25(15).

PMID: 39125772 PMC: 11311839. DOI: 10.3390/ijms25158202.

The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets.

Reed J, Bain S, Kanamarlapudi V Diabetes Metab Syndr Obes. 2024; 17:2419-2456.

PMID: 38894706 PMC: 11184168. DOI: 10.2147/DMSO.S415934.

Incretin and glucagon receptor polypharmacology in chronic kidney disease.

McFarlin B, Duffin K, Konkar A Am J Physiol Endocrinol Metab. 2024; 326(6):E747-E766.

PMID: 38477666 PMC: 11551006. DOI: 10.1152/ajpendo.00374.2023.

Sensory Nutrition and Bitterness and Astringency of Polyphenols.

Osakabe N, Shimizu T, Fujii Y, Fushimi T, Calabrese V Biomolecules. 2024; 14(2).

PMID: 38397471 PMC: 10887135. DOI: 10.3390/biom14020234.

References

Lee Y, Wang M, Du X, Charron M, Unger R . Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes. 2011; 60(2):391-7. PMC: 3028337. DOI: 10.2337/db10-0426. View

Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B . A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006; 29(10):2189-95. DOI: 10.2337/dc06-0042. View

Petersen K, Sullivan J . Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 2001; 44(11):2018-24. DOI: 10.1007/s001250100006. View

Balas B, Baig M, Watson C, Dunning B, Ligueros-Saylan M, Wang Y . The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007; 92(4):1249-55. DOI: 10.1210/jc.2006-1882. View

Porksen N, Munn S, Steers J, Veldhuis J, Butler P . Impact of sampling technique on appraisal of pulsatile insulin secretion by deconvolution and cluster analysis. Am J Physiol. 1995; 269(6 Pt 1):E1106-14. DOI: 10.1152/ajpendo.1995.269.6.E1106. View

Yu R, Nissen N, Dhall D, Heaney A . Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature. Pancreas. 2008; 36(4):428-31. DOI: 10.1097/MPA.0b013e31815ceb23. View

Liang Y, Osborne M, Monia B, Bhanot S, Gaarde W, Reed C . Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes. 2004; 53(2):410-7. DOI: 10.2337/diabetes.53.2.410. View

Chia C, Carlson O, Kim W, Shin Y, Charles C, Kim H . Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes. 2009; 58(6):1342-9. PMC: 2682676. DOI: 10.2337/db08-0958. View

Shah P, Vella A, Basu A, Basu R, Schwenk W, Rizza R . Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000; 85(11):4053-9. DOI: 10.1210/jcem.85.11.6993. View

10.

Parker J, McPherson R, Andrews K, Levy C, Dubins J, Chin J . Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes. 2000; 49(12):2079-86. DOI: 10.2337/diabetes.49.12.2079. View

11.

Juhl C, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J . Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002; 51(2):424-9. DOI: 10.2337/diabetes.51.2.424. View

12.

Rosenstock J, Foley J, Rendell M, Landin-Olsson M, Holst J, Deacon C . Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2007; 31(1):30-5. DOI: 10.2337/dc07-1616. View

13.

Garber A, Henry R, Ratner R, Garcia-Hernandez P, Rodriguez-Pattzi H, Olvera-Alvarez I . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2008; 373(9662):473-81. DOI: 10.1016/S0140-6736(08)61246-5. View

14.

Silvestre R, Jodka C, Parkes D, Pittner R, Young A, Marco J . Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab. 2001; 280(3):E443-9. DOI: 10.1152/ajpendo.2001.280.3.E443. View

15.

He Y, Serra D, Wang Y, Campestrini J, Riviere G, Deacon C . Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007; 46(7):577-88. DOI: 10.2165/00003088-200746070-00003. View

16.

Menge B, Gruber L, Jorgensen S, Deacon C, Schmidt W, Veldhuis J . Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes. 2011; 60(8):2160-8. PMC: 3142077. DOI: 10.2337/db11-0251. View

17.

Herman G, Bergman A, Stevens C, Kotey P, Yi B, Zhao P . Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006; 91(11):4612-9. DOI: 10.1210/jc.2006-1009. View

18.

Fineman M, Koda J, Shen L, Strobel S, Maggs D, Weyer C . The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002; 51(5):636-41. DOI: 10.1053/meta.2002.32022. View

19.

Madsen P, Kodra J, Behrens C, Nishimura E, Jeppesen C, Pridal L . Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties. J Med Chem. 2009; 52(9):2989-3000. DOI: 10.1021/jm8016249. View

20.

SCHULMAN J, CARLETON J, Whitney G, WHITEHORN J . Effect of glucagon on food intake and body weight in man. J Appl Physiol. 1957; 11(3):419-21. DOI: 10.1152/jappl.1957.11.3.419. View